Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)

The aim of the research was to develop a galenical formulation for the combination of the three probiotic strains Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3 and Bifidobacterium bifidum MF 20/5 that would lead to the presence of a high amount of viable cells in the small intestine,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Letters in applied microbiology 2019-11, Vol.69 (5), p.325-332
Hauptverfasser: Venema, K., Verhoeven, J., Verbruggen, S., Espinosa, L., Courau, S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 332
container_issue 5
container_start_page 325
container_title Letters in applied microbiology
container_volume 69
creator Venema, K.
Verhoeven, J.
Verbruggen, S.
Espinosa, L.
Courau, S.
description The aim of the research was to develop a galenical formulation for the combination of the three probiotic strains Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3 and Bifidobacterium bifidum MF 20/5 that would lead to the presence of a high amount of viable cells in the small intestine, the presumed site of action of these strains. This was tested in a validated, dynamic in vitro model of the stomach and small intestine (TIM‐1), simulating human adults after intake of a meal. Experiments were performed both in the gastric compartment of the model, as well as in the complete system (stomach + small intestine). Survival of the strains in an unformulated probiotic powder after transit through the gastric compartment was 5·3% for the bifidobacteria and 1% for L. gasseri. After transit through the complete gastrointestinal tract, this dropped to 2% for bifidobacteria and 0·1% for Lactobacillus. After several rounds of optimization, an enteric‐coated tablet was developed that increased the delivery of viable cells reaching the small intestine to 72% (gastric survival) for bifidobacteria, and 53% (gastric) for L. gasseri. Also survival in the small intestine increased by about an order of magnitude. The final galenical formulation was tested in two applications: adults and elderly, both of which have their own physiological parameters. These experiments corroborated the results obtained in the development phase of the project. In conclusion, the developed enteric coating led to a 20‐ to 40‐fold increase in the delivery of viable cells to the small intestine. Significance and Impact of the Study Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver >10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains. Significance and Impact of the Study: Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver >10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains.
doi_str_mv 10.1111/lam.13211
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6856813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2352423827</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4411-3192e0f834050a474dee6c113fc70fe46a909e8ffd8170a2c6d66909214bfc123</originalsourceid><addsrcrecordid>eNqFks9qFTEUhwdR7G114QtIwE0LTpuTyWTmboRS_FO4RRcV3IXczJnelGRyTTIjd-cj9DF8Lp_E1KlFBTGbkJzvfOSEX1E8A3oMeZ1Y5Y6hYgAPigXwhpWNqD89LBaUCVG2rOZ7xX6M15TSFtjycbFXAa85Z_Wi-PYh-LXxyWgSxzCZSVnSjcEMV0QRN9pkvn-9sWqHATuS1NpiIh1OaP3W4ZCIiiRhTLlohtzR7QbljH5JtHfbMWHI3doPKXhrZ2Yy-UCc79AS35O0QRKTd0pviBo6Ep2yNnO3UjMgObw8v8gOOHpSPOqVjfj0bj8oPr55fXn2rly9f3t-droqNecAZQVLhrRvK05rqnjDO0ShAapeN7RHLtSSLrHt-66FhiqmRSdEvmLA170GVh0Ur2bvdlw77HQeMigrt8E4FXbSKyP_rAxmI6_8JEVbixaqLDi8EwT_ecxjSGeiRmvVgH6MklU146xqWfN_lLXQirpuIKMv_kKv_RiG_BNZSBsqspZn6mimdPAxBuzv3w1U3kZF5qjIn1HJ7PPfB70nf2UjAycz8MVY3P3bJFenF7PyB_-QzTg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2307062354</pqid></control><display><type>article</type><title>Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Venema, K. ; Verhoeven, J. ; Verbruggen, S. ; Espinosa, L. ; Courau, S.</creator><creatorcontrib>Venema, K. ; Verhoeven, J. ; Verbruggen, S. ; Espinosa, L. ; Courau, S.</creatorcontrib><description>The aim of the research was to develop a galenical formulation for the combination of the three probiotic strains Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3 and Bifidobacterium bifidum MF 20/5 that would lead to the presence of a high amount of viable cells in the small intestine, the presumed site of action of these strains. This was tested in a validated, dynamic in vitro model of the stomach and small intestine (TIM‐1), simulating human adults after intake of a meal. Experiments were performed both in the gastric compartment of the model, as well as in the complete system (stomach + small intestine). Survival of the strains in an unformulated probiotic powder after transit through the gastric compartment was 5·3% for the bifidobacteria and 1% for L. gasseri. After transit through the complete gastrointestinal tract, this dropped to 2% for bifidobacteria and 0·1% for Lactobacillus. After several rounds of optimization, an enteric‐coated tablet was developed that increased the delivery of viable cells reaching the small intestine to 72% (gastric survival) for bifidobacteria, and 53% (gastric) for L. gasseri. Also survival in the small intestine increased by about an order of magnitude. The final galenical formulation was tested in two applications: adults and elderly, both of which have their own physiological parameters. These experiments corroborated the results obtained in the development phase of the project. In conclusion, the developed enteric coating led to a 20‐ to 40‐fold increase in the delivery of viable cells to the small intestine. Significance and Impact of the Study Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver &gt;10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains. Significance and Impact of the Study: Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver &gt;10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains.</description><identifier>ISSN: 0266-8254</identifier><identifier>EISSN: 1472-765X</identifier><identifier>DOI: 10.1111/lam.13211</identifier><identifier>PMID: 31454425</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adult ; Adults ; Aged ; Bifidobacterium ; Bifidobacterium - growth &amp; development ; Bifidobacterium bifidum ; Bifidobacterium longum ; cell viability ; coatings ; Computer simulation ; Drug Compounding ; elderly ; Gastrointestinal system ; Gastrointestinal tract ; Geriatrics ; Humans ; Impact prediction ; Intestine ; Intestine, Small - microbiology ; Lactobacillus ; Lactobacillus - growth &amp; development ; Lactobacillus gasseri ; Microbial Viability ; multi‐layered tablet ; Optimization ; Original ; probiotic ; Probiotics ; Probiotics - chemistry ; Small intestine ; Stomach ; Stomach - microbiology ; Survival ; Tablets - chemistry ; TIM‐1 ; Transit ; Yogurt</subject><ispartof>Letters in applied microbiology, 2019-11, Vol.69 (5), p.325-332</ispartof><rights>2019 The Authors. published by John Wiley &amp; Sons Ltd on behalf of Society for Applied Microbiology.</rights><rights>2019 The Authors. Letters in Applied Microbiology published by John Wiley &amp; Sons Ltd on behalf of Society for Applied Microbiology.</rights><rights>Copyright © 2019 The Society for Applied Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4411-3192e0f834050a474dee6c113fc70fe46a909e8ffd8170a2c6d66909214bfc123</citedby><cites>FETCH-LOGICAL-c4411-3192e0f834050a474dee6c113fc70fe46a909e8ffd8170a2c6d66909214bfc123</cites><orcidid>0000-0001-7046-5127</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Flam.13211$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Flam.13211$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31454425$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Venema, K.</creatorcontrib><creatorcontrib>Verhoeven, J.</creatorcontrib><creatorcontrib>Verbruggen, S.</creatorcontrib><creatorcontrib>Espinosa, L.</creatorcontrib><creatorcontrib>Courau, S.</creatorcontrib><title>Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)</title><title>Letters in applied microbiology</title><addtitle>Lett Appl Microbiol</addtitle><description>The aim of the research was to develop a galenical formulation for the combination of the three probiotic strains Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3 and Bifidobacterium bifidum MF 20/5 that would lead to the presence of a high amount of viable cells in the small intestine, the presumed site of action of these strains. This was tested in a validated, dynamic in vitro model of the stomach and small intestine (TIM‐1), simulating human adults after intake of a meal. Experiments were performed both in the gastric compartment of the model, as well as in the complete system (stomach + small intestine). Survival of the strains in an unformulated probiotic powder after transit through the gastric compartment was 5·3% for the bifidobacteria and 1% for L. gasseri. After transit through the complete gastrointestinal tract, this dropped to 2% for bifidobacteria and 0·1% for Lactobacillus. After several rounds of optimization, an enteric‐coated tablet was developed that increased the delivery of viable cells reaching the small intestine to 72% (gastric survival) for bifidobacteria, and 53% (gastric) for L. gasseri. Also survival in the small intestine increased by about an order of magnitude. The final galenical formulation was tested in two applications: adults and elderly, both of which have their own physiological parameters. These experiments corroborated the results obtained in the development phase of the project. In conclusion, the developed enteric coating led to a 20‐ to 40‐fold increase in the delivery of viable cells to the small intestine. Significance and Impact of the Study Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver &gt;10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains. Significance and Impact of the Study: Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver &gt;10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains.</description><subject>Adult</subject><subject>Adults</subject><subject>Aged</subject><subject>Bifidobacterium</subject><subject>Bifidobacterium - growth &amp; development</subject><subject>Bifidobacterium bifidum</subject><subject>Bifidobacterium longum</subject><subject>cell viability</subject><subject>coatings</subject><subject>Computer simulation</subject><subject>Drug Compounding</subject><subject>elderly</subject><subject>Gastrointestinal system</subject><subject>Gastrointestinal tract</subject><subject>Geriatrics</subject><subject>Humans</subject><subject>Impact prediction</subject><subject>Intestine</subject><subject>Intestine, Small - microbiology</subject><subject>Lactobacillus</subject><subject>Lactobacillus - growth &amp; development</subject><subject>Lactobacillus gasseri</subject><subject>Microbial Viability</subject><subject>multi‐layered tablet</subject><subject>Optimization</subject><subject>Original</subject><subject>probiotic</subject><subject>Probiotics</subject><subject>Probiotics - chemistry</subject><subject>Small intestine</subject><subject>Stomach</subject><subject>Stomach - microbiology</subject><subject>Survival</subject><subject>Tablets - chemistry</subject><subject>TIM‐1</subject><subject>Transit</subject><subject>Yogurt</subject><issn>0266-8254</issn><issn>1472-765X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNqFks9qFTEUhwdR7G114QtIwE0LTpuTyWTmboRS_FO4RRcV3IXczJnelGRyTTIjd-cj9DF8Lp_E1KlFBTGbkJzvfOSEX1E8A3oMeZ1Y5Y6hYgAPigXwhpWNqD89LBaUCVG2rOZ7xX6M15TSFtjycbFXAa85Z_Wi-PYh-LXxyWgSxzCZSVnSjcEMV0QRN9pkvn-9sWqHATuS1NpiIh1OaP3W4ZCIiiRhTLlohtzR7QbljH5JtHfbMWHI3doPKXhrZ2Yy-UCc79AS35O0QRKTd0pviBo6Ep2yNnO3UjMgObw8v8gOOHpSPOqVjfj0bj8oPr55fXn2rly9f3t-droqNecAZQVLhrRvK05rqnjDO0ShAapeN7RHLtSSLrHt-66FhiqmRSdEvmLA170GVh0Ur2bvdlw77HQeMigrt8E4FXbSKyP_rAxmI6_8JEVbixaqLDi8EwT_ecxjSGeiRmvVgH6MklU146xqWfN_lLXQirpuIKMv_kKv_RiG_BNZSBsqspZn6mimdPAxBuzv3w1U3kZF5qjIn1HJ7PPfB70nf2UjAycz8MVY3P3bJFenF7PyB_-QzTg</recordid><startdate>201911</startdate><enddate>201911</enddate><creator>Venema, K.</creator><creator>Verhoeven, J.</creator><creator>Verbruggen, S.</creator><creator>Espinosa, L.</creator><creator>Courau, S.</creator><general>Oxford University Press</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7ST</scope><scope>7T7</scope><scope>7TM</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>M7N</scope><scope>P64</scope><scope>SOI</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7046-5127</orcidid></search><sort><creationdate>201911</creationdate><title>Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)</title><author>Venema, K. ; Verhoeven, J. ; Verbruggen, S. ; Espinosa, L. ; Courau, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4411-3192e0f834050a474dee6c113fc70fe46a909e8ffd8170a2c6d66909214bfc123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Adults</topic><topic>Aged</topic><topic>Bifidobacterium</topic><topic>Bifidobacterium - growth &amp; development</topic><topic>Bifidobacterium bifidum</topic><topic>Bifidobacterium longum</topic><topic>cell viability</topic><topic>coatings</topic><topic>Computer simulation</topic><topic>Drug Compounding</topic><topic>elderly</topic><topic>Gastrointestinal system</topic><topic>Gastrointestinal tract</topic><topic>Geriatrics</topic><topic>Humans</topic><topic>Impact prediction</topic><topic>Intestine</topic><topic>Intestine, Small - microbiology</topic><topic>Lactobacillus</topic><topic>Lactobacillus - growth &amp; development</topic><topic>Lactobacillus gasseri</topic><topic>Microbial Viability</topic><topic>multi‐layered tablet</topic><topic>Optimization</topic><topic>Original</topic><topic>probiotic</topic><topic>Probiotics</topic><topic>Probiotics - chemistry</topic><topic>Small intestine</topic><topic>Stomach</topic><topic>Stomach - microbiology</topic><topic>Survival</topic><topic>Tablets - chemistry</topic><topic>TIM‐1</topic><topic>Transit</topic><topic>Yogurt</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Venema, K.</creatorcontrib><creatorcontrib>Verhoeven, J.</creatorcontrib><creatorcontrib>Verbruggen, S.</creatorcontrib><creatorcontrib>Espinosa, L.</creatorcontrib><creatorcontrib>Courau, S.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Environment Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environment Abstracts</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Letters in applied microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Venema, K.</au><au>Verhoeven, J.</au><au>Verbruggen, S.</au><au>Espinosa, L.</au><au>Courau, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)</atitle><jtitle>Letters in applied microbiology</jtitle><addtitle>Lett Appl Microbiol</addtitle><date>2019-11</date><risdate>2019</risdate><volume>69</volume><issue>5</issue><spage>325</spage><epage>332</epage><pages>325-332</pages><issn>0266-8254</issn><eissn>1472-765X</eissn><abstract>The aim of the research was to develop a galenical formulation for the combination of the three probiotic strains Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3 and Bifidobacterium bifidum MF 20/5 that would lead to the presence of a high amount of viable cells in the small intestine, the presumed site of action of these strains. This was tested in a validated, dynamic in vitro model of the stomach and small intestine (TIM‐1), simulating human adults after intake of a meal. Experiments were performed both in the gastric compartment of the model, as well as in the complete system (stomach + small intestine). Survival of the strains in an unformulated probiotic powder after transit through the gastric compartment was 5·3% for the bifidobacteria and 1% for L. gasseri. After transit through the complete gastrointestinal tract, this dropped to 2% for bifidobacteria and 0·1% for Lactobacillus. After several rounds of optimization, an enteric‐coated tablet was developed that increased the delivery of viable cells reaching the small intestine to 72% (gastric survival) for bifidobacteria, and 53% (gastric) for L. gasseri. Also survival in the small intestine increased by about an order of magnitude. The final galenical formulation was tested in two applications: adults and elderly, both of which have their own physiological parameters. These experiments corroborated the results obtained in the development phase of the project. In conclusion, the developed enteric coating led to a 20‐ to 40‐fold increase in the delivery of viable cells to the small intestine. Significance and Impact of the Study Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver &gt;10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains. Significance and Impact of the Study: Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver &gt;10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>31454425</pmid><doi>10.1111/lam.13211</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-7046-5127</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0266-8254
ispartof Letters in applied microbiology, 2019-11, Vol.69 (5), p.325-332
issn 0266-8254
1472-765X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6856813
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Adult
Adults
Aged
Bifidobacterium
Bifidobacterium - growth & development
Bifidobacterium bifidum
Bifidobacterium longum
cell viability
coatings
Computer simulation
Drug Compounding
elderly
Gastrointestinal system
Gastrointestinal tract
Geriatrics
Humans
Impact prediction
Intestine
Intestine, Small - microbiology
Lactobacillus
Lactobacillus - growth & development
Lactobacillus gasseri
Microbial Viability
multi‐layered tablet
Optimization
Original
probiotic
Probiotics
Probiotics - chemistry
Small intestine
Stomach
Stomach - microbiology
Survival
Tablets - chemistry
TIM‐1
Transit
Yogurt
title Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T10%3A33%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Probiotic%20survival%20during%20a%20multi%E2%80%90layered%20tablet%20development%20as%20tested%20in%20a%20dynamic,%20computer%E2%80%90controlled%20in%20vitro%20model%20of%20the%20stomach%20and%20small%20intestine%20(TIM%E2%80%901)&rft.jtitle=Letters%20in%20applied%20microbiology&rft.au=Venema,%20K.&rft.date=2019-11&rft.volume=69&rft.issue=5&rft.spage=325&rft.epage=332&rft.pages=325-332&rft.issn=0266-8254&rft.eissn=1472-765X&rft_id=info:doi/10.1111/lam.13211&rft_dat=%3Cproquest_pubme%3E2352423827%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2307062354&rft_id=info:pmid/31454425&rfr_iscdi=true